A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache

Perrotta, Armando; Biondi‐Zoccai, Giuseppe; Saade, Wael; Miraldi, Fabio; Morelli, Andrea; Marullo, Antonino G. M.; Carnevale, Roberto; Falco, Elena De; Chimenti, Isotta; Sciarretta, Sebastiano; Frati, Paola; Mamas, Mamas A.; Ciardi, Sara; Frati, Luigi; Frati, Giacomo; Peruzzi, Mariangela

doi:10.23736/s0031-0808.21.04435-9

Cited by 8 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…inactivated viruses or recombinant viral vectors) ones, together with a minor impact of age, which enables presuming that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. After almost two years since the beginning of the COVID-19 pandemic, the SARS-CoV-2 is still causing a large number of deaths worldwide, and vaccination campaign is the most promising and safe way to reduce its spreading: this in fact means to reduce the impact of COVID-19 on the health of citizens [111], by reducing mortality but also by reducing morbidity and long term impact of COVID-19, and in particular to protect the health and wellbeing of the weakest ones [112]. Like all vaccines, also those used to prevent SARS-CoV-2 spreading and the risks connected to the development of COVID-19 may produce AEs: among them, headache is one of the most common.…”

Section: Discussionmentioning

confidence: 99%

Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are used to reduce the risk of developing Coronavirus Disease 2019 (COVID-19). Despite the significant benefits in terms of reduced risk of hospitalization and death, different adverse events may present after vaccination: among them, headache is one of the most common, but nowadays there is no summary presentation of its incidence and no description of its main features. Methods We searched PubMed and EMBASE covering the period between January 1st 2020 and August 6th, 2021, looking for record in English and with an abstract and using three main search terms (with specific variations): COVID-19/SARS-CoV-2; Vaccination; headache/adverse events. We selected manuscript including information on subjects developing headache after injection, and such information had to be derived from a structured form (i.e. no free reporting). Pooled estimates and 95% confidence intervals were calculated. Analyses were carried out by vaccine vs. placebo, by first vs. second dose, and by mRNA-based vs. “traditional” vaccines; finally, we addressed the impact of age and gender on post-vaccine headache onset. Results Out of 9338 records, 84 papers were included in the review, accounting for 1.57 million participants, 94% of whom received BNT162b2 or ChAdOx1. Headache was generally the third most common AE: it was detected in 22% (95% CI 18–27%) of subjects after the first dose of vaccine and in 29% (95% CI 23–35%) after the second, with an extreme heterogeneity. Those receiving placebo reported headache in 10–12% of cases. No differences were detected across different vaccines or by mRNA-based vs. “traditional” ones. None of the studies reported information on headache features. A lower prevalence of headache after the first injection of BNT162b2 among older participants was shown. Conclusions Our results show that vaccines are associated to a two-fold risk of developing headache within 7 days from injection, and the lack of difference between vaccine types enable to hypothesize that headache is secondary to systemic immunological reaction than to a vaccine-type specific reaction. Some descriptions report onset within the first 24 h and that in around one-third of the cases, headache has migraine-like features with pulsating quality, phono and photophobia; in 40–60% of the cases aggravation with activity is observed. The majority of patients used some medication to treat headache, the one perceived as the most effective being acetylsalicylic acid.

show abstract

Section: Discussionmentioning

confidence: 99%

Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Joint or muscle pain, tenderness, itching, and paresthesia in the injection site. [24][25][26][27][28]31,34 Local effects were also greater in previously infected individuals than in those who had never been infected. Fever, chills, fatigue, headache, nausea, myalgia, pyrexia, and dyspnea are among the systemic side effects.…”

Section: Types Of Adverse Reactionsmentioning

confidence: 96%

“…The 11 studies were undertaken the United States, the United Kingdom, Canada, Peru, the United Arab Emirates, and South Korea and most of the studies taking place in developed countries. [24][25][26][27][28][29][30][31][32][33][34] The majority of the studies had similar contexts, but the populations varied and were conducted in general community populations, with the remainder conducted in healthcare professionals, armed forces personnel, and patients with systemic lupus and cancer. The objectives of most of the studies were to investigate the adverse reactions after those populations vaccinated with COVID-19 vaccines.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Fever, chills, fatigue, headache, nausea, myalgia, pyrexia, and dyspnea are among the systemic side effects. [24][25][26][27][28][29][31][32][33][34] Some cardiovascular side effects like sinus tachycardia, premature ventricular contractions, and right bundle branch block may occur. 33 The vast majority of patients who reported unfavorable cardiovascular events were men.…”

Section: Types Of Adverse Reactionsmentioning

confidence: 99%

“…The adverse responses seen by participants following the first dose of COVID-19 vaccinations are modest, with local pain and fever, according to the studies included. [24][25][26][27][28][29][30][31][32][33][34] Another study, on the other hand, discovered that moderate to severe reactogenicity was more typically observed after immunization dose two. 27 These side effects were more common after the second dose than after the first.…”

Section: Types Of Adverse Reactionsmentioning

confidence: 99%

See 2 more Smart Citations

Adverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies

Dhamanti¹,

Suwantika²,

Adlia³

et al. 2023

IJGM

View full text Add to dashboard Cite

The COVID-19 pandemic had a severe global impact. A range of campaigns and activities, including vaccines, are being implemented to counteract this pandemic. Using observational data, the goal of this scoping review is to identify adverse events connected with COVID-19 vaccinations. We conduct a scoping study and searched three databases from the start of the COVID-19 pandemic in 2020 through June 2022. Based on our criteria and searched keywords, the review included eleven papers in total, with the majority of the studies being conducted in developed countries. The study populations varied and included general community populations, healthcare professionals, military forces, and patients with systemic lupus and cancer. This study includes vaccines from Pfizer-BioNTech, Oxford-AstraZeneca, Sinopharm, and Moderna. The COVID-19 vaccine-related adverse events were classified into three types: local side effects, systemic side effects, and other side effects such as allergies. The adverse reactions to COVID-19 vaccines are mild to moderate in severity, with no significant influence or interference in individual daily activities and no unique patterns in cause of death among vaccine-related deaths. According to the findings of these investigations, the COVID-19 vaccine is safe to administer and induces protection. It is vital to convey accurate information to the public about vaccination side effects, potential adverse responses, and the safety level of the vaccines supplied. Multiple strategies must be implemented at the individual, organizational, and population levels to eliminate vaccine hesitance. Future studies could investigate the vaccine's effect on people of various ages and medical conditions.

show abstract

Comprehensive evaluation of the effect of inactivated SARS‐CoV‐2 vaccination on female fertility: A retrospective cohort study

Ba,

Yang,

Zhu

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Fear of possible negative effects of coronavirus disease 2019 (COVID‐19) vaccine on fertility is the main reason for vaccine hesitancy among the public especially women of childbearing age. Despite the high coverage of COVID‐19 vaccination in China, more scientific evidence is still needed to address their concerns and guide fertility counseling and management in the future. Herein, we performed a retrospective cohort study at a single large center for reproductive medicine in China between August 2020 and May 2023. Patients aged 20–42 years with no history of laboratory‐confirmed COVID‐19 were included and categorized into different groups according to their vaccination status. The serum sex hormone levels, anti‐Müllerian hormone concentrations, embryo quality, and pregnancy outcomes were evaluated and compared among them. We found there were no significant differences in the concentrations of follicle‐stimulating hormone, luteinizing hormone and progesterone between the unvaccinated, first‐dose, second‐dose, and booster vaccinated groups. However, the estradiol showed a highly significant increase in the one‐dose vaccinated group compared with its levels in other groups. Among unvaccinated and either vaccinated patients, anti‐Müllerian hormone levels were comparable (p = 0.139). The number of oocytes retrieved, fertilization rate and good‐quality embryo rate were all similar between each group of in vitro fertilization and intracytoplasmic sperm injection. No significant differences were observed regarding other laboratory parameters. Moreover, the vaccination status of infertile couples did not exert any adverse effect on the pregnancy outcomes in all assisted reproductive technologies cycles. In short, we comprehensively evaluated the reproductive safety of inactivated severe acute respiratory syndrome coronavirus 2 vaccine and found any dose of vaccination wouldn't negatively affect female fertility parameters such as sex hormone levels and ovarian reserve. Moreover, this is the first study to complete the live birth follow‐up of the cohort after receiving inactivated severe acute respiratory syndrome coronavirus 2 vaccine, further dispelling the misconception and providing reassurance for decision‐making by clinicians.

show abstract

A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache

Cited by 8 publications

References 18 publications

Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

Adverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies

Comprehensive evaluation of the effect of inactivated SARS‐CoV‐2 vaccination on female fertility: A retrospective cohort study

Contact Info

Product

Resources

About